Skip to main content

Table 2 Physician and parent/patient reported outcome measures, composite disease activity score and prevalence inactive disease at the cross-sectional visit*

From: Clinical insights into heterogeneity of rheumatoid factor negative polyarticular juvenile idiopathic arthritis across the world

 

Northern Europe

N = 223

Western Europe

N = 198

Southern Europe

N = 480

Eastern Europe

N = 539

North America

N = 165

Latin America

N = 217

Africa & Middle East

N = 271

Southeast Asia

N = 48

Physician-centered measures

 Swollen joint count > 0

73 (32.7)

83 (41.9)

169 (35.2)

271 (50.3)

60 (36.4)

110 (50.7)

122 (45.0)

11 (22.9)

 Tender joint count > 0

87 (39.0)

82 (41.4)

129 (26.9)

282 (52.3)

51 (30.9)

83 (38.2)

138 (50.9)

11 (22.9)

 Limited joint count > 0

94 (42.2)

110 (55.6)

197 (41.0)

309 (57.3)

80 (48.5)

130 (59.9)

152 (56.1)

22 (45.8)

 Active joint count > 0

84 (37.7)

93 (47.0)

184 (38.3)

315 (58.4)

69 (41.8)

117 (53.9)

146 (53.9)

13 (27.1)

 Active joint count (median [IQR])

0.0 [0.0, 1.0]

0.0 [0.0, 2.0]

0.0 [0.0, 2.0]

1.0 [0.0, 6.0]

0.0 [0.0, 2.0]

1.0 [0.0, 4.0]

1.0 [0.0, 4.0]

0.0 [0.0, 1.0]

 Less than 5 active joints

203 (91.0)

169 (85.4)

430 (89.6)

384 (71.2)

141 (85.5)

164 (75.6)

222 (81.9)

44 (91.7)

 5 to 9 active joints

14 (6.3)

16 (8.1)

32 (6.7)

75 (13.9)

16 (9.7)

27 (12.4)

29 (10.7)

1 (2.1)

 10 active joints or more

6 (2.7)

13 (6.6)

18 (3.8)

80 (14.8)

8 (4.8)

26 (12.0)

20 (7.4)

3 (6.2)

 PhGA > 0§

135 (60.5)

128 (64.6)

237 (49.5)

432 (80.1)

98 (59.4)

131 (60.4)

206 (76.0)

24 (50.0)

 PhGA (median [IQR])

1.0 [0.0, 2.0]

1.0 [0.0, 2.9]

0.0 [0.0, 2.0]

2.0 [0.5, 4.0]

1.0 [0.0, 2.5]

1.0 [0.0, 3.0]

2.5 [0.5, 4.2]

0.2 [0.0, 1.5]

 JADI score > 0#

37 (31.1)

20 (28.2)

48 (25.4)

114 (52.8)

18 (24.7)

45 (42.9)

47 (53.4)

9 (56.2)

 JADI-articular score > 0#

31 (26.1)

15 (21.1)

36 (19.0)

99 (45.8)

15 (20.5)

44 (41.9)

42 (47.7)

8 (50.0)

 JADI-extra-articular score > 0#

15 (12.6)

8 (11.3)

23 (12.2)

59 (27.3)

6 (8.2)

12 (11.4)

27 (30.3)

5 (31.2)

Parent/patient reported measures

 PaGA > 0§

169 (76.1)

164 (82.8)

250 (52.5)

393 (73.5)

101 (62.7)

119 (54.8)

183 (68.5)

27 (56.2)

 PaGA (median [IQR])

1.5 [0.5, 3.5]

2.0 [1.0, 5.0]

0.5 [0.0, 3.0]

1.5 [0.0, 4.0]

0.5 [0.0, 2.5]

0.5 [0.0, 2.5]

2.0 [0.0, 5.0]

0.5 [0.0, 2.0]

 Pain intensity > 0§

165 (74.3)

151 (76.3)

226 (47.5)

383 (71.6)

112 (69.6)

120 (55.3)

162 (60.7)

23 (47.9)

 Pain intensity (median [IQR])

1.8 [0.0, 4.5]

2.0 [0.5, 5.0]

0.0 [0.0, 2.5]

1.5 [0.0, 4.0]

1.0 [0.0, 3.0]

0.5 [0.0, 2.0]

1.5 [0.0, 5.0]

0.0 [0.0, 2.5]

 Morning stiffness > 15 min

76 (34.7)

62 (31.6)

62 (13.1)

122 (22.8)

36 (22.4)

42 (19.4)

52 (19.8)

7 (14.6)

 Physical function score > 0†

143 (64.4)

130 (66.0)

230 (48.1)

344 (64.3)

88 (54.7)

124 (57.1)

193 (71.5)

26 (54.2)

 HRQoL score > SD 1 in healthy children‡

147 (67.4)

130 (67.4)

219 (48.5)

359 (68.8)

84 (53.8)

114 (53.3)

189 (71.1)

19 (41.3)

Composite disease activity scores

        

 cJADAS10 (median [IQR])

3.0 [0.5, 7.0]

5.0 [1.5, 9.5]

2.0 [0.0, 7.0]

6.5 [1.5, 13.0]

3.0 [0.5, 7.5]

3.5 [0.0, 11.0]

7.0 [1.5, 12.0]

2.0 [0.0, 5.0]

 JADAS10 (median [IQR])

3.0 [1.0, 7.4]

4.9 [2.0, 8.5]

2.2 [0.0, 7.3]

7.0 [2.0, 14.1]

3.0 [0.5, 7.5]

3.6 [0.3, 12.0]

6.7 [1.5, 13.5]

2.5 [0.3, 6.1]

Inactive disease

        

 By ACR clinically inactive disease [17]

67 (30.0)

51 (25.8)

203 (42.3)

86 (16.0)

59 (35.8)

68 (31.3)

52 (19.2)

16 (33.3)

 By ACR 2021 cJADAS10 criteria [16]

104 (46.8)

75 (37.9)

268 (56.3)

174 (32.5)

80 (49.7)

103 (47.5)

84 (31.5)

30 (62.5)

  1. IQR interquartile range, PhGA physician global assessment of disease activity, JADI Juvenile Arthritis Damage Index, PaGA parent global assessment of disease activity, HRQoL health-related quality of life scale, SD standard deviation, cJADAS10 clinical Juvenile Arthritis Disease Activity Score 10, JADAS10 Juvenile Arthritis Disease Activity Score 10, ACR American College of Rheumatology
  2. *Values are numbers (%) unless indicated otherwise. All the differences are statistically significant (p < 0.001). See main text for the post-hoc analysis
  3. §Measured with a visual analogue scale on a 21-numbered circle visual analogue scale, ranging from 0 (best) to 10 (worst)
  4. #The JADI score is computed only in patients with a disease duration longer than 5 years
  5. †Score ranges from 0 (no disability) to 45 (maximum disability). ‡Score ranges from 0 to 30, with higher scores indicating worse HRQoL. The SD in healthy children was calculated for each geographical area on questionnaires completed by the parents of these children
Back to article page

Pediatric Rheumatology

ISSN: 1546-0096